SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media platforms are seeing a surge in speculative chatter as investors debate the legitimacy of tokenized pre-IPO assets, with many users warning of potential scams while others track news regarding a long-rumored SpaceX public offering. Community members are actively analyzing the aerospace sector, focusing on the potential impact of a high-profile IPO and debating whether current market excitement reflects genuine valuation or a bubble driven by retail FOMO.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is attracting significant attention as investors speculate on its role in the AI-agent infrastructure space, with the community actively discussing potential institutional interest and long-term utility. Despite recent price volatility, supporters are highlighting bullish ecosystem developments and active development as reasons to maintain a long-term position.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement for the Tokyo strain of BCG to address the ongoing domestic shortage, a move the community views as a strategic breakthrough that strengthens the company's competitive position against major pharmaceutical players. Investors are actively discussing the potential for accelerated regulatory pathways, the synergy between this supply and Anktiva, and the anticipation of further catalysts being revealed at the upcoming American Urological Association conference.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The community is actively discussing $DEGEN, pointing to a mix of optimism surrounding potential exchange listings and a new beta app while others express frustration over token performance. Investors remain hyper-focused on upcoming project catalysts and social media branding as they debate whether the token is currently at a critical accumulation phase.

Ideal Power, Inc. engages in the development of power converter solutions for photovoltaic generation, grid-storage and electrified vehicle charging. Its products include solar inverters, bi-directional battery, electric vehicle chargers, photovoltaic inverters and battery converters. It is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. The company was founded by William C. Alexander on May 17, 2007 and is headquartered in Austin, TX.

Ideal Power Inc

Ideal Power is trending as investors monitor its progress in commercializing B-TRAN technology, highlighted by the early completion of its first major solid-state circuit breaker design win in Asia. The community is focused on the stock's potential for institutional adoption and institutional validation as it targets a multibillion-dollar market for power semiconductors in data centers, EVs, and renewable energy.

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

WW International Inc - Ordinary Shares - New

WW International, Inc. Common Stock

WW International is gaining traction as investors speculate on a turnaround driven by strategic partnerships with GLP-1 medication providers and debt-reduction efforts. The community remains divided, with some betting on a successful pivot toward clinical weight-loss solutions while others remain skeptical due to the company's historical financial struggles and competitive pressure.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor Q4 earnings results and weigh the ongoing growth of immunology blockbusters Skyrizi and Rinvoq against the managed decline of Humira revenues. Meanwhile, community discussions are heavily focused on the company's potential M&A appetite in the obesity and oncology sectors, with retail sentiment remaining vigilant regarding potential competitive threats and pipeline expansion strategies.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is experiencing a surge in investor interest driven by strong prescription growth, successful patent protection, and a clear path toward operating profitability in the coming quarters. The community is actively discussing the stock's potential for acquisition by larger pharmaceutical firms, while closely monitoring the ongoing battle against high short interest and institutional accumulation patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomerica, Inc. Q2 Loss Widens

(RTTNews) - Biomerica, Inc. (BMRA) announced earnings for its second quarter that Increased from the same period last year...

Shares of Biomerica, Inc. (BMRA) traded nearly 26% lower on Wednesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biomerica.com/news/news-details/2025/Biomerica-Announces-Reverse-Stock-Split/default.aspx">said</a> it would implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock to increase its bid price.The stock split will be effective at 12:01 a.m. ET on April 21, and Biomerica’s common stock will begin trading on a split-adjusted basis when the market opens on Monday, the company said.Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock, subsequently reducing the number of outstanding shares from about 20.4 million to about 2.5 million.The move is aimed at enabling the biomedical technology company to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market.To regain compliance, Biomerica’s common stock must close at or above a $1.00 per share bid price for at least ten consecutive business days prior to May 5.On Stocktwits, retail sentiment around Biomerica fell from ‘extremely bullish’ to ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’.<figure class="image"><img style="aspect-ratio:1306/306;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_1_33_21_PM_png_82a4f25b9a.webp" alt="BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1306" height="306"><figcaption>BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that today marks a good opportunity to buy the stock as the reverse split is “not that big of a deal” and the company has a strong cash runway.<stembedurl>https://stocktwits.com/ildamiano1/message/611809693</stembedurl>Biomerica’s cash and cash equivalents totaled $3.06 million as of February-end, marking an increase from $2.37 million at the end of the second quarter (Q2) of fiscal 2025.<a href="https://stocktwits.com/symbol/BMRA">BMRA stock</a> is up by about 42% year-to-date but has fallen 43% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-made-900-million-dollars-from-china-business-in-2024-report/chQPqv2RbOH">Ford Made $900M From China Business In 2024, Says Report: Retail Sentiment Brightens But Still Bearish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Biomerica Stock Slumps After Reverse Stock Split Announcement: Retail’s Disappointed

Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.

Equity

Medical diagnostic product maker Biomerica Inc. emerged as the top biotech stock with the highest jump in new retail followers on Stocktwits Friday.Shares of the nanocap company tumbled over 9% on Friday afternoon, following a 100% surge in the prior session — its best single-day performance since March 18, 2020, when the stock more than quadrupled.On Thursday, Biomerica announced that its Fortel Prostate Specific Antigen (PSA) Screening Test received approval from the UAE Ministry of Health and Prevention.&nbsp;The test offers rapid and accurate results in just 10 minutes using a simple finger-prick blood sample, measuring PSA levels, an established early marker of prostate disease.The accessible nature of the test is designed to facilitate early detection of prostate cancer and related conditions, aiming to improve patient outcomes, reduce strain on healthcare systems, and encourage proactive health management, the company said.The UAE approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.&nbsp;The company previously achieved regional success with its EZ Detect Colon Disease At-Home Screening Test, which secured government insurance reimbursement in Dubai.Biomerica said it is working to replicate this success with the Fortel PSA test, establishing partnerships with key distributors and securing regulatory approvals to improve accessibility to early cancer detection solutions.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BMRA_sentiment_and_message_volume_Jan_17_cec1cb6947.png" alt="BMRA sentiment and message volume Jan 17.png" width="1318" height="324"><figcaption>BMRA sentiment and message volume Jan 17 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Despite Friday’s stock dip, likely driven by profit-taking, retail sentiment on Stocktwits remained ‘bullish’, with a notable rise in message volume.&nbsp;Many retail investors indicated they were “buying the dip,” as chatter about the stock soared.<stembedurl>https://stocktwits.com/chaudaaary/message/600490675</stembedurl><stembedurl>https://stocktwits.com/Gunsmoke16/message/600488437</stembedurl><stembedurl>https://stocktwits.com/543688Ireland/message/600474360</stembedurl>Biomerica’s retail follower count on Stocktwits has climbed nearly 5% over the past year, while message volume has soared over a thousand-fold, even as the stock has shed more than 31% in value during the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prostate cancer cells, 3D illustration. Prostate cancer awareness image. | Image source: KATERYNA KON/SCIENCE PHOTO LIBRARY via Getty Images

Biomerica Adds Most New Retail Followers Among Biotechs After UAE Nod For Prostate Cancer Screening Test

The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

BMRA
Biomerica Inc.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest BMRA News

BMRABiomerica Inc.